biotechnology
biotechnology on Beyond Market Intelligence: a running collection of 5 stories we have gathered and hand-picked because they are worth your time. Every post here touches on biotechnology in some way — the news, the analysis, the deep dives, and the occasional surprise find. Acme AI is the next-generation, AI-powered spreadsheet platform built to replace Excel and redefine how analysts, data scientists, and enterprise teams work with data. New stories are added to this page as we find them, so check back if you want to keep up with what is happening around biotechnology, or subscribe to the RSS feed to get them as soon as they are published. Browse the collection below, or head back to the homepage to see everything Beyond Market Intelligence is covering right now.
Michael Polansky is training an AI model on skin that’s still alive
Michael Polansky, known for his association with Lady Gaga and his past role with Sean Parker, is quietly pioneering a novel approach to skincare innovation. His startup cultivates living human skin tissue outside the body for weeks, using AI to identify promising new compounds. This groundbreaking work represents a significant shift in how we discover and develop skincare solutions. Interestingly, recent Nvidia research highlights the crucial role of infrastructure—the “harness”—in ensuring AI stability, a concept relevant to Polansky’s work.
The Enhanced Games — tech’s steroid extravaganza — didn’t pay off, as company posts $60 million loss
The Enhanced Games, a venture aiming to transform sports through performance-enhancing technology, has reported a significant $60 million loss. This outcome underscores the financial realities facing ambitious ventures, a point highlighted in our recent article, "Learn what VCs actually want, from a founder who’s raised $1B." While innovation in fields like energy, as explored by Apollo Atomics, can demonstrate promise, the Enhanced Games’ experience serves as a clear reminder of the importance of financial prudence and market viability.
AI isn’t close to curing cancer. This startup says it knows what it will take.
The pursuit of AI-driven medical breakthroughs often overstates near-term possibilities. While a cure for cancer remains distant, a new startup is focusing on a fundamental truth: it’s the data, stupid. Their approach prioritizes meticulous data curation and intelligent modeling—a pragmatic strategy for unlocking insights hidden within complex biological datasets. This emphasis on foundational data practices represents a crucial shift, mirroring the innovative techniques explored in our recent piece, "Trained an diffusion model that runs on 264KB of RAM."
Colossal Biosciences reportedly in talks to raise new capital at $20B–$30B valuation
Colossal Biosciences, the ambitious startup focused on de-extinction, is reportedly exploring a significant new capital raise. Sources indicate the company is targeting a valuation between $20 billion and $30 billion – a potential doubling or tripling of its previous assessment. This move underscores the growing investor interest in the intersection of biotechnology and synthetic biology. For those tracking the broader AI investment landscape, the recent $15 million raise by inference startup Infinity offers further insight into current market dynamics.
OpenAI researcher Miles Wang in talks to launch AI drug discovery startup valued at $2B
Prominent OpenAI researcher Miles Wang is reportedly in discussions to launch an AI-driven drug discovery startup, potentially valued at $2 billion. This signals significant investor confidence in applying artificial intelligence to accelerate breakthroughs within the life sciences. The anticipated venture aims to transform pharmaceutical research through innovative AI applications. For a deeper dive into advanced AI systems, explore our breakdown of the Claude Fable 5 system prompt. This development underscores the growing momentum of AI across diverse industries.